JP2017525738A - 皮膚におけるバリア機能のuv誘導性喪失の処置に使用される局所プテロスチルベン組成物 - Google Patents
皮膚におけるバリア機能のuv誘導性喪失の処置に使用される局所プテロスチルベン組成物 Download PDFInfo
- Publication number
- JP2017525738A JP2017525738A JP2017512286A JP2017512286A JP2017525738A JP 2017525738 A JP2017525738 A JP 2017525738A JP 2017512286 A JP2017512286 A JP 2017512286A JP 2017512286 A JP2017512286 A JP 2017512286A JP 2017525738 A JP2017525738 A JP 2017525738A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- pterostilbene
- topical
- individual
- loss
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
Description
本願は、2014年9月4日に出願された米国仮出願第62/046,068号の利益を主張し、これは本明細書中に参照によって組み込まれる。
本発明は、国立がん研究所によって授与された助成金第P30CA62330号、および国立環境健康科学研究所によって授与された助成金第R03ES019668号のもとの政府支援で行われた。政府は、本発明においてある一定の権利を有する。
プテロスチルベンは、in vitroにおいて、レスベラトロールより生物学的利用能が大きい。
SKH−1マウスの皮膚における経表皮水分喪失量(TEWL)を含む有害なUV−Bに媒介される損傷を防止する、プテロスチルベン処置。
別の実施形態では、SKH−1マウスにおける、UVに媒介されるSCCの防止における経口プテロスチルベンの有効性を実証することができる。
Claims (14)
- 個体における皮膚におけるUVに媒介されるDNA損傷を処置、阻害、または防止するための化学保護方法であって、このような処置を必要とする前記個体に、有効量のプテロスチルベン化合物を投与するステップを含む、化学保護方法。
- 前記個体が、ヒトである、請求項1に記載の化学保護方法。
- 前記プテロスチルベン化合物が、薬学的に、または栄養補助物質として許容される担体を含む組成物で提供される、前記請求項のいずれかに記載の化学保護方法。
- 総用量に対するプテロスチルベンの前記有効量が、前記組成物の総重量に基づき約0.1重量%〜約10重量%の範囲内である、前記請求項のいずれかに記載の化学保護方法。
- 総1日用量に対するプテロスチルベンの前記有効量が、約1mg〜約1000mgの範囲内である、前記請求項のいずれかに記載の化学保護方法。
- 前記化合物の投与経路が、経口、局所、皮内、経皮、および皮下からなる群から選択される、前記請求項のいずれかに記載の化学保護方法。
- 前記皮膚における損傷が、乾癬、ケロイド形成、光線性角化症(AK)、基底細胞癌、および扁平細胞癌からなる群から選択される細胞増殖性障害を含む、前記請求項のいずれかに記載の化学保護方法。
- 個体における皮膚におけるUVに媒介されるDNA損傷により引き起こされる、皮膚におけるバリア機能の喪失を処置、阻害、または防止するための局所方法であって、このような処置を必要とする前記個体の皮膚表面に、有効量のプテロスチルベン化合物を投与するステップを含む、局所方法。
- 前記個体が、ヒトである、請求項8に記載の局所方法。
- 前記プテロスチルベン化合物を、薬学的に許容される担体を含む組成物により提供する、請求項8または9に記載の局所方法。
- 総用量に対するプテロスチルベンの前記有効量が、前記組成物の総重量に基づき約0.1重量%〜約10重量%の範囲内である、請求項8から10のいずれかに記載の局所方法。
- 総1日用量に対するプテロスチルベンの前記有効量が、約1mg〜約1000mgの範囲内である、請求項8から11のいずれかに記載の局所方法。
- 前記皮膚における損傷が、乾癬、ケロイド形成、光線性角化症(AK)、基底細胞癌、および扁平細胞癌からなる群から選択される細胞増殖性障害を含む、請求項8から12のいずれかに記載の局所方法。
- 経表皮水分喪失量(TEWL)により示される皮膚におけるバリア機能の喪失を含む前記皮膚における損傷が軽減される、前記請求項のいずれかに記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462046068P | 2014-09-04 | 2014-09-04 | |
US62/046,068 | 2014-09-04 | ||
PCT/US2015/048422 WO2016036999A1 (en) | 2014-09-04 | 2015-09-03 | Topical pterostilbene compositions for use in treating uv-induced loss of barrier function in skin |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017525738A true JP2017525738A (ja) | 2017-09-07 |
JP2017525738A5 JP2017525738A5 (ja) | 2018-10-04 |
Family
ID=55436471
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017512286A Pending JP2017525738A (ja) | 2014-09-04 | 2015-09-03 | 皮膚におけるバリア機能のuv誘導性喪失の処置に使用される局所プテロスチルベン組成物 |
Country Status (11)
Country | Link |
---|---|
US (1) | US9980924B2 (ja) |
EP (1) | EP3194032B1 (ja) |
JP (1) | JP2017525738A (ja) |
KR (1) | KR20170045343A (ja) |
CN (1) | CN107106877A (ja) |
AU (1) | AU2015311799A1 (ja) |
BR (1) | BR112017004304B1 (ja) |
CA (1) | CA2959756C (ja) |
MX (1) | MX2017002818A (ja) |
WO (1) | WO2016036999A1 (ja) |
ZA (1) | ZA201701510B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019055932A (ja) * | 2017-09-20 | 2019-04-11 | 学校法人同志社 | Dj−1タンパク質産生促進用組成物 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2959756C (en) | 2014-09-04 | 2023-02-28 | The Regents Of The University Of California | Topical pterostilbene compositions for use in treating uv-induced loss of barrier function in skin |
WO2018034328A1 (ja) * | 2016-08-17 | 2018-02-22 | 香港友池有限公司 | プテロスチルベン配糖体を含む外用組成物 |
EP4029496A1 (en) * | 2021-01-18 | 2022-07-20 | Universitat de València | Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2820975B1 (fr) * | 2001-02-21 | 2004-03-12 | Oreal | Composition pour application topique comprenant au moins un hydroxystilbene et au moins un polyol pour solubiliser l'hydroxystilbene |
US20090047309A1 (en) | 2007-08-13 | 2009-02-19 | Maes Daniel H | Cosmetic methods and compositions for repairing human skin |
US8703161B2 (en) | 2007-08-13 | 2014-04-22 | Elc Management, Llc | Skin repair compositions comprising circadian gene activators and a synergistic combination of Sirt1 gene activators |
US20100240767A1 (en) * | 2009-03-23 | 2010-09-23 | Muhammed Majeed | Melanogenesis inhibitiuon by 3,5-dimethoxy-4'-hydroxystilbenes and cosmeceutical compositions thereof |
EP2322159A1 (en) * | 2009-10-30 | 2011-05-18 | Green Molecular, S.L. | Use of pterostilbene (pter) as medicament for prevention and/or treatment of skin diseases, damages or injures or as cosmetic |
US8841350B2 (en) * | 2011-05-11 | 2014-09-23 | ChromaDex Inc. | Method for inducing UDP-glucuronosyltransferase activity using pterostilbene |
US20130296440A1 (en) | 2012-05-01 | 2013-11-07 | ChromaDex Inc. | Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation |
CN103239540B (zh) * | 2013-04-03 | 2014-11-12 | 广东药学院 | 一种凉血愈伤方提取物及治疗皮肤烧伤的复方白藜芦醇凉血愈伤油制剂 |
CA2959756C (en) | 2014-09-04 | 2023-02-28 | The Regents Of The University Of California | Topical pterostilbene compositions for use in treating uv-induced loss of barrier function in skin |
WO2016037007A1 (en) | 2014-09-04 | 2016-03-10 | The Regents Of The University Of California | Topical pterostilbene compositions for use in treating uv-induced skin damage and hyperplasia |
-
2015
- 2015-09-03 CA CA2959756A patent/CA2959756C/en active Active
- 2015-09-03 US US14/845,173 patent/US9980924B2/en active Active
- 2015-09-03 WO PCT/US2015/048422 patent/WO2016036999A1/en active Application Filing
- 2015-09-03 JP JP2017512286A patent/JP2017525738A/ja active Pending
- 2015-09-03 CN CN201580059094.2A patent/CN107106877A/zh active Pending
- 2015-09-03 AU AU2015311799A patent/AU2015311799A1/en not_active Abandoned
- 2015-09-03 EP EP15838274.7A patent/EP3194032B1/en active Active
- 2015-09-03 MX MX2017002818A patent/MX2017002818A/es active IP Right Grant
- 2015-09-03 BR BR112017004304-1A patent/BR112017004304B1/pt not_active IP Right Cessation
- 2015-09-03 KR KR1020177009080A patent/KR20170045343A/ko not_active IP Right Cessation
-
2017
- 2017-02-28 ZA ZA2017/01510A patent/ZA201701510B/en unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019055932A (ja) * | 2017-09-20 | 2019-04-11 | 学校法人同志社 | Dj−1タンパク質産生促進用組成物 |
JP7061766B2 (ja) | 2017-09-20 | 2022-05-02 | 学校法人同志社 | Dj-1タンパク質産生促進用組成物 |
Also Published As
Publication number | Publication date |
---|---|
AU2015311799A1 (en) | 2017-03-30 |
CA2959756A1 (en) | 2016-03-10 |
WO2016036999A1 (en) | 2016-03-10 |
BR112017004304A2 (pt) | 2017-12-05 |
CA2959756C (en) | 2023-02-28 |
BR112017004304B1 (pt) | 2020-12-08 |
US20160067194A1 (en) | 2016-03-10 |
ZA201701510B (en) | 2018-11-28 |
CN107106877A (zh) | 2017-08-29 |
EP3194032A1 (en) | 2017-07-26 |
EP3194032A4 (en) | 2018-05-23 |
EP3194032B1 (en) | 2021-06-23 |
MX2017002818A (es) | 2017-08-02 |
US9980924B2 (en) | 2018-05-29 |
KR20170045343A (ko) | 2017-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yaghoobi et al. | Vitiligo: a review of the published work | |
Amini et al. | Nonsurgical innovations in the treatment of nonmelanoma skin cancer | |
US20120258060A1 (en) | Methods for protecting the skin from radiation insults | |
Alam et al. | The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA | |
Visnagri et al. | Elucidation of ameliorative effect of Co-enzyme Q10 in streptozotocin-induced diabetic neuropathic perturbation by modulation of electrophysiological, biochemical and behavioral markers | |
Yarosh et al. | Anti-inflammatory activity in skin by biomimetic of Evodia rutaecarpa extract from traditional Chinese medicine | |
JP2017525738A (ja) | 皮膚におけるバリア機能のuv誘導性喪失の処置に使用される局所プテロスチルベン組成物 | |
US8029770B2 (en) | Caffeine salt complexes and methods for using the same in the prevention or treatment of cancer | |
IL235449A (en) | Method for Identifying ahr Receptor Ligands with Suppressive Medical Activity Fat Excretion and the Ligands | |
ES2559454T3 (es) | Composición que comprende dihidroquercetina, alfa-tocoferol y bisabolol | |
JP2012232991A (ja) | 炎症改善のための生体模倣エボジアルテカルパ果実抽出物 | |
Fabbrocini et al. | A peel‐off facial mask comprising myoinositol and trehalose‐loaded liposomes improves adult female acne by reducing local hyperandrogenism and activating autophagy | |
Likar et al. | Pharmacokinetic and pharmacodynamic properties of tramadol IR and SR in elderly patients: a prospective, age-group-controlled study | |
Coopman et al. | Phototherapy with ultraviolet B | |
US20160067193A1 (en) | Topical pterostilbene compositions for use in treating uv-induced skin damage and hyperplasia | |
JP2021505621A (ja) | Pde−4阻害剤の局所軟膏製剤および皮膚状態の治療におけるそれらの使用 | |
Casale et al. | Clinical role of oral vitamin C and E therapy in skin and hair disorders | |
CN117377475A (zh) | 治疗与糖尿病性周围神经病变相关的疼痛 | |
CN113543773B (zh) | 稳定的局部用非诺多泮组合物 | |
US20180296530A1 (en) | Method for treating atopic dermatitis | |
Reichrath et al. | The Epidemiology of basal cell and squamous cell carcinoma | |
TW201632182A (zh) | 治療皮膚之腫瘤及癌前病理的雷公藤內酯及其衍生物 | |
Pustišek et al. | A review of sunscreens and their adverse reactions | |
US11559541B2 (en) | Topical capecitabine for the treatment of hyperproliferative skin conditions | |
Jeong et al. | Antimelanogenic activity of a novel adamantyl benzylbenzamide derivative, AP 736: a randomized, double‐blind, vehicle‐controlled comparative clinical trial performed in patients with hyperpigmentation during the summer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180824 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180824 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190604 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190903 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191105 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200302 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20201006 |